Description: PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey.
Home Page: www.pmvpharma.com
PMVP Technical Analysis
8 Clarke Drive
Cranbury,
NJ
08512
United States
Phone:
609 642 6670
Officers
| Name | Title |
|---|---|
| Dr. David H. Mack Ph.D. | Co-Founder, CEO, Pres & Director |
| Dr. Arnold J. Levine Ph.D. | Co-Founder, Independent Director & Member of Scientific Advisory Board |
| Mr. Winston Kung M.B.A. | COO & CFO |
| Dr. Deepika Jalota Pharm.D. | Chief Regulatory & Quality Assurance Officer |
| Dr. Leila Alland M.D. | Chief Medical Officer |
| Dr. Thomas E. Shenk Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Mr. Robert Ticktin | Gen. Counsel & Company Sec. |
| Mr. Tim Smith | Sr. VP & Head of Corp. Devel. |
| Dr. Binh Vu Ph.D. | Sr. VP of Drug Discovery & CMC |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6976 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-09-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 54 |